Spine BioPharma is a biopharmaceutical company developing non-opiate, non-surgical therapies for chronic low back pain caused by DDD. The company raised $13.5 million in its latest round of funding, which is sure to hasten the advancement of the company’s lead candidate, SB-01, to offer hope to millions suffering from debilitating spine conditions.

Company Overview

Founded in 2015 and based in New York City, Spine BioPharma is dedicated to the goal of therapeutic solutions for diseases of the spine. Their treatments aim to reduce pain, restore function, halt, or reverse pathological diseases of the spine without recourse to opioids or invasive surgical intervention. The lead product from this company is SB-01, a first-in-class therapeutic that targets the treatment of DDD, a disorder that afflicts a large proportion of adults

Related post

Culina Health Secures $7.9M to Expand Personalized Nutrition Services

Corsmed Secures €3.3 Million to Revolutionize MRI Technology

Funding Details

The latest $13.5 million funding includes both equity and debt financing through undisclosed investors. This strategic investment reflects growing confidence in Spine BioPharma’s innovative approach to chronic low back pain and the potential of SB-01 to transform the treatment landscape for DDD.

SB-01: A Novel Therapeutic Approach

SB-01 is a peptide with 7 amino acids composed in such a way as to be directed to the degradation of transforming growth factor-beta 1, TGFβ1, a protein usually overexpressed by patients suffering from lower back pain. Increased levels of TGFβ1 have been related to enhanced inflammation and the degradation of the extracellular matrix as well as enhanced discogenic pain via stimulation of nerve growth factors. It thus attempts to downregulate the TGFβ1 activity through this approach.

• Reduce Inflammation: Relieving pain and discomfort related to DDD.
• Enhance Extracellular Matrix Production: Preserving or restoring spinal disc structural integrity.
• Decrease Nerve Sensitization: Minimizing pain and improving patient mobility.

This novel approach could be a new route for managing DDD with the possibility of avoiding or delaying surgical interventions.

Clinical Development and Future Plans

Funds obtained from the financing round are used to further clinical development for SB-01. The Company is dedicated to the phase of clinical studies that makes SB-01’s safety and efficacy profile more comprehensive. Spine BioPharma is looking forward to offering a non-opiate, non-surgical treatment alternative for patients with chronic low back pain resulting from DDD, addressing a sizeable unmet medical need.

Degenerative Disc Disease: A prevalent concern

Degenerative disc disease is caused by the breakdown of intervertebral discs, resulting in chronic pain, loss of function, and reduced quality of life. It is ranked as the number one source of disability in the whole world. The available curative treatment is mostly drugs and medication or invasive surgery accompanied by physiotherapy or even surgical procedures. Hence, SB-01 marked a breakthrough in offering effective minimally invasive treatment for this massive disease.